X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hematology (48) 48
humans (46) 46
index medicus (43) 43
oncology (37) 37
female (32) 32
male (32) 32
adult (31) 31
middle aged (30) 30
aged (29) 29
chronic myeloid leukemia (26) 26
medical and health sciences (25) 25
medicin och hälsovetenskap (25) 25
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (22) 22
aged, 80 and over (20) 20
imatinib mesylate (20) 20
leukemia (20) 20
chronic myelogenous leukemia (19) 19
clinical medicine (18) 18
klinisk medicin (18) 18
imatinib (17) 17
adolescent (16) 16
young adult (16) 16
analysis (15) 15
chronic myeloid-leukemia (15) 15
leukemia, myelogenous, chronic, bcr-abl positive - mortality (15) 15
medicine & public health (15) 15
therapy (15) 15
dasatinib (14) 14
treatment outcome (14) 14
tyrosine kinase inhibitors (13) 13
care and treatment (12) 12
leukemia, myelogenous, chronic, bcr-abl positive - genetics (12) 12
nilotinib (12) 12
hematologi (11) 11
hemic and lymphatic diseases (11) 11
prognosis (11) 11
protein kinase inhibitors - administration & dosage (11) 11
pyrimidines - administration & dosage (11) 11
risk factors (11) 11
cancer (10) 10
cml (10) 10
piperazines - administration & dosage (10) 10
piperazines - therapeutic use (10) 10
pyrimidines - therapeutic use (10) 10
survival (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
interferon-alpha (9) 9
molecular response (9) 9
protein kinase inhibitors - therapeutic use (9) 9
recommendations (9) 9
abridged index medicus (8) 8
antineoplastic agents - therapeutic use (8) 8
follow-up (8) 8
leukemia, myelogenous, chronic, bcr-abl positive - therapy (8) 8
myeloid leukemia (8) 8
treatment-free remission (8) 8
benzamides - administration & dosage (7) 7
chronic-phase (7) 7
clinical trials (7) 7
cml patients (7) 7
disease-free survival (7) 7
fusion proteins, bcr-abl - genetics (7) 7
kaplan-meier estimate (7) 7
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (7) 7
patients (7) 7
stem-cell transplantation (7) 7
survival analysis (7) 7
antineoplastic agents (6) 6
bcr-abl transcripts (6) 6
benzamides (6) 6
benzamides - therapeutic use (6) 6
cancer research (6) 6
internal medicine (6) 6
leukemia, myelogenous, chronic, bcr-abl positive - pathology (6) 6
quality of life (6) 6
remission induction (6) 6
research (6) 6
tyrosine (6) 6
acute lymphoblastic-leukemia (5) 5
antineoplastic agents - administration & dosage (5) 5
cancer and oncology (5) 5
cancer och onkologi (5) 5
clinical-trials (5) 5
diagnosis (5) 5
europe (5) 5
european leukemianet (5) 5
follow-up studies (5) 5
germany (5) 5
interferon (5) 5
minimal residual disease (5) 5
oncology, experimental (5) 5
protein kinase inhibitors - adverse effects (5) 5
randomized cml (5) 5
remission (5) 5
time factors (5) 5
age (4) 4
age factors (4) 4
antimitotic agents (4) 4
article (4) 4
bcr-abl (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 04/2011, Volume 29, Issue 12, pp. 1634 - 1642
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism
Journal Article
Karger Kompass Onkologie, ISSN 2296-5416, 09/2019, Volume 6, Issue 3, pp. 134 - 134
Journal Article
Karger Kompass Onkologie, ISSN 2296-5416, 09/2019, Volume 6, Issue 3, pp. 146 - 147
Two decades after the introduction of tyrosine kinase inhibitors (TKI), a sizeable portion of patients with chronic myeloid leukemia (CML) in chronic phase... 
Wissenstransfer
Journal Article
Karger Kompass Onkologie, ISSN 2296-5416, 2019, Volume 6, Issue 3, pp. 146 - 147
Journal Article
Karger Kompass Onkologie, ISSN 2296-5416, 2019, Volume 6, Issue 3, pp. 134 - 134
Journal Article
Im Focus Onkologie, ISSN 1435-7402, 02/2018, Volume 21, Issue 1-2, pp. 27 - 27
Journal Article
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 6, pp. 872 - 884
Journal Article
Journal Article
Im Focus Onkologie, ISSN 1435-7402, 02/2016, Volume 19, Issue 1-2, pp. 68 - 68
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1645 - 1645
BACKGROUND AND AIMS Real-world data on usage of 1st, 2nd and 3rd generation TKIs in CML are limited. Furthermore, current information on cost of CML treatment... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5364 - 5364
The accumulation of DNA damage and the alteration of the DNA damage response (DDR) are critical features of genetic instability that is presumed to be... 
Journal Article
Annals of Hematology, ISSN 0939-5555, 12/2015, Volume 94, Issue 12, pp. 2015 - 2024
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 747 - 757
Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a... 
SURVIVAL | MAJOR MOLECULAR RESPONSE | TREATMENT-FREE REMISSION | ONCOLOGY | IMATINIB DISCONTINUATION | DISEASE | FOLLOW-UP | DASATINIB | WITHDRAWAL SYNDROME | NILOTINIB | PHASE-2 TRIAL | Predictive Value of Tests | Prospective Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Clinical Decision-Making | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Polymerase Chain Reaction | Adult | Female | Biomarkers, Tumor - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Drug Administration Schedule | Risk Assessment | Europe | Risk Factors | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Progression-Free Survival | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Antimitotic agents | Tyrosine | Antineoplastic agents | Analysis | Life Sciences | Hematology | Human health and pathology | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article